These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2005-003463-23 ADJUVANT TREATMENT OF FULLY RESECTED STAGE III COLON CANCER WITH FOLFOX-4 VERSUS FOLFOX-4 PLUS CETUXIMAB 2016-10-15 due-trials
Exempt 2006-004770-27 TRAITEMENT NEOADJUVANT DU CANCER DE L’ŒSOPHAGE OPERABLE A VISEE CURATIVE PAR 5-FLUOROURACILE, CISPLATINE ET CETUXIMAB + RADIOTHERAPIE CONCOMITANTE. ÉTUDE DE PHASE I-II not-yet-due
Completed, but no date 2007-001772-37 Essai de phase II, multicentrique, évaluant le G-CSF en prophylaxie primaire associé au schéma de chimiothérapie FOLFIRI + bévacizumab en 1ère ligne dans le cancer colorectal métastatique chez des pat... bad-data
Completed, but no date Terminated 2008-005959-19 Etude de phase II non contrôlée: traitement de première ligne par sunitinib plus folfiri pour les patients ayant un cancer du rectum avec des métastases synchrones résécables (SUREMETS) bad-data
Ongoing 2008-007928-25 ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAP... not-yet-due
Completed, but no date Terminated 2009-014443-36 Carcinome hépatocellulaire avancé sur cirrhose Child B : étude de tolérance et d’efficacité du Torisel® (Temsirolimus) bad-data
Reported results 2009-017064-16 Essai randomisé en double aveugle de phase II/III évaluant la chimioembolisation combinée au sunitinib ou à un placebo chez des patients atteints de carcinome hépatocellulaire (SATURNE) 2021-06-18 due-trials
Reported results 2009-017996-11 ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAP... 2019-03-19 due-trials
Reported results 2010-022987-11 PHARMACOGENETIQUE DE LA GEMCITABINE : ETUDE DE L’IMPACT DU POLYMORPHISME GENETIQUE DE LA CYTIDINE DEAMINASE (CDA) SUR LA TOXICITE ET L’EFFICACITE THERAPEUTIQUE DANS LES ADENOCARCINOMES PANCREATIQUES R... 2016-09-15 due-trials
Not reported 2010-023115-33 Essai évaluant l'efficacité et la tolérance d'une chimiothérapie péri-opératoire par 5FU-Cisplatine-Cetuximab dans les adénocarcinomes de l'estomac et de la jonction oesogastrique. Phase II monobras, ... 2019-11-04 due-trials
Exempt 2011-005436-26 Etude de phase I-II de radiochimiothérapie associée au panitumumab dans le traitement des carcinomes épidermoïdes localisés de l'anus not-yet-due
Ongoing 2011-006266-41 FFCD 1102 ETUDE DE PHASE II : TRAITEMENT DE PREMIERE LIGNE PAR FOLFIRINOX POUR LES PATIENTS AYANT UN CANCER DU RECTUM AVEC METASTASES SYNCHRONES NON RESECABLES FFCD 1102 ETUDE DE PHASE II : TRAITE... not-yet-due
Not reported 2012-002224-32 Evérolimus comme traitement après embolisation ou chimioembolisation de métastases hépatiques de tumeur endocrine digestive 2016-11-18 due-trials
Not reported 2012-004166-18 Intra-arterial hepatic beads loaded with irinotecan (Debiri) with concomitant chemotherapy with FOLFOX in patients with colorectal cancer with unresectable liver metastases: a phase II multicenter stu... 2018-11-29 due-trials
Reported results 2013-004069-14 A european, multicentre, phase II/III randomised double-blind, placebo controlled study evaluating lanreotide as maintenance therapy in patients with non-resectable duodeno-pancreatic neuroendocrine t... 2019-09-25 due-trials
Completed, but no date, and reported results 2013-004081-33 EFFICACY AND SAFETY of aflibercept ASSOCIATED WITH A FOLFIRI CHEMOTHERAPY IN 1ST LINE TREATMENT OF PATIENTS SUFFERING FROM METASTATIC COLORECTAL CANCER Phase II - single arm - multicenter EFFICACI... bad-data
Not reported 2014-000050-10 Chemoembolisation of patient with hepatocellular carcinoma, not selective for a curative treatment, by microsphere charged with idarubicin Chimioembolisation des carcinomes hépatocellulaires ne re... 2021-03-31 due-trials
Completed, but no date 2014-001837-10 PHASE II RANDOMIZED TRIAL EVALUATING AFLIBERCEPT ASSOCIATED WITH SCHEME LV5FU2 AS FIRST LINE TREATMENT OF NON-RESECTABLE METASTATIC COLORECTAL CANCERS ETUDE DE PHASE II RANDOMISEE EVALUANT L’AFLIBE... bad-data
Ongoing 2014-002517-39 Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more ETUDE DE PHASE III RANDOMISEE EVALUANT LA CHIMI... not-yet-due
Completed, but no date, and reported results 2014-002574-36 Phase II randomized study evaluation of FOLFIRINOX +/- LV5FU2 in maintenance and FIRGEM in 1rst line of metastatic pancreas cancer Phase II randomisée dans le cancer pancréatique métastatique évalu... bad-data
Completed, but no date 2014-004449-28 A randomized multicenter phase II trial of a sequential chemotherapy of nab-paclitaxel + gemcitabine followed by FOLFIRI.3 versus nab-paclitaxel + gemcitabine in first line of pancreatic adenocarcinom... bad-data
Reported results 2015-002086-29 PHASE II STUDY EVALUATION OF EFFICACITY AND TOLERANCE OF REGORAFENIB FOR 70 YEARS OLD AND MORE PATIENTS WITH A METASTATIC COLORECTAL ADENOCARCIMA ETUDE DE PHASE II EVALUANT L’EFFICACITE ET LA TOLE... 2018-10-17 due-trials
Completed, but no date 2016-001225-13 PHASE II RANDOMISEE EVALUANT L’EFFICACITE ET LA TOLERANCE DE 2 STRATEGIES THERAPEUTIQUES COMBINANT LE BEVACIZUMAB A LA CHIMIOTHERAPIE: DESESCALADE VERSUS ESCALADE CHEZ DES PATIENTS AYANT UN CANCER COL... bad-data
Other 2016-002331-16 Essai de phase III randomisé évaluant le FOLFOX avec ou sans DOCETAXEL (TFOX) en 1ère ligne de chimiohtérapie des adénocarcinomes oeso-gastriques localement avancés ou métastatiques not-yet-due
Other 2016-002393-12 Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 and targeted therapy in first-line treatment of metastatic colorectal cancer restricted to the liver Oxaliplatine systém... not-yet-due
Other 2016-004575-49 MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATE... not-yet-due
Other 2017-001587-38 A phase II study evaluating FOLFOX + panitumumab according to a "stop and go" strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment, as the first line in p... not-yet-due
Other 2017-001683-37 SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patients SecOnde ligne de Chimiothérapie avec RAmucirumab +/- pacliTaxel che... not-yet-due
Other 2017-004309-41 Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pa... not-yet-due
Ongoing 2017-004730-28 Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA Nal-IRI/LV5FU VERSUS PACLITAXEL EN DEUXIEME LIGNE DE TRAITEMENT CHEZ LES PAT... not-yet-due
Ongoing 2018-002014-13 A randomized phase II study evaluating FOLFIRI + durvalumab vs FOLFIRI + durvalumab and tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarc... not-yet-due
Other 2019-002400-40 A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB (IMMUNE CHEKPOINT INHIBITOR) IN ... not-yet-due
Other 2019-002407-18 FFCD 1703 -POCHI PEMBROLIZUMAB IN COMBINATION WITH XELOX BEVACIZUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE: A PROOF OF CONCEPT STUDY P... not-yet-due
Other 2021-000828-35 FFCD 2006 – NEORAF STUDY A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING IN PATIENTS WITH LOCALISED COLON CANCER AND THE BRAF V600... not-yet-due